Quantumzyme Seeks Regulatory Approval for Name Change to Quantum Genesis AI

Quantumzyme Corp. announced that its Board of Directors has approved a proposed corporate name change to Quantum Genesis AI Corp. The company will submit the required notice to the Financial Industry Regulatory Authority, which will include a request to update its ticker symbol. The proposed change will take effect only following FINRA approval. The rebranding reflects the company's strategic intent to align its identity more closely with its expanding integration of artificial intelligence into its enzyme engineering initiatives.

This prospective evolution of the corporate name is intended to signal the company's forward-looking approach as it continues to develop technologies designed to support environmentally conscious pharmaceutical production. While the name change remains subject to regulatory approval, the proposed identity of Quantum Genesis AI represents the direction in which research and development efforts are heading. This prospective evolution aligns with continued work toward combining intelligence-driven computational tools with sustainable chemistry to support long-term strategy.

The company's proprietary technology framework integrates quantum mechanics, molecular modeling, machine learning, and computational design principles. These tools are intended to support the development of biocatalysts capable of contributing to more sustainable and efficient pharmaceutical manufacturing methods. The platform is being advanced to explore opportunities to streamline traditional chemical steps through enzyme-enabled alternatives, with the goal of reducing process inefficiencies typically associated with legacy manufacturing approaches.

Quantumzyme has been progressing its enzyme engineering initiatives through recent achievements such as laboratory-scale samples of enzymatic ibuprofen prepared for external evaluation and peer-reviewed research published in RSC Sustainability. These developments support the company's broader intent to apply its methodologies across additional high-volume Active Pharmaceutical Ingredients as part of its expanding research pipeline. The company continues to evaluate how its enzyme engineering framework may contribute to environmental improvements within pharmaceutical manufacturing.

Specific design goals include supporting the reduction of chemical waste, minimizing solvent use, and lowering the carbon intensity associated with traditional synthesis processes. While further validation and scale-up will be required, Quantumzyme intends to demonstrate how its sustainability-focused approach may offer economic and environmental advantages relative to conventional chemical manufacturing routes. As research advances, the company is assessing opportunities for partnerships, technology licensing, and collaborative development programs.

The company believes that its strategic initiatives, combined with the prospective name change, may enhance its visibility within markets focused on AI-driven innovation, sustainable chemistry, and domestic pharmaceutical manufacturing resilience. These efforts align with broader industry trends emphasizing environmental responsibility and supply-chain stability. The objective is to position the company for future opportunities by aligning technological evolution with a corporate identity that reflects growth strategy.

Quantumzyme anticipates that its combination of AI-enabled modeling, enzyme engineering capabilities, and sustainability-focused development priorities may support long-term expansion into multiple API categories. This prospective diversification is part of the company's broader strategy to create value through innovation while contributing to the future of responsible manufacturing. The company will proceed with submitting the required corporate action request to FINRA, which must review and approve the proposed name change and any associated ticker symbol updates before they take effect.